CRISPR Therapeutics - CRSP Stock Forecast, Price & News

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR Therapeutics Stock Up 1.5 %

CRSP Stock opened at $78.66 on Friday. CRISPR Therapeutics has a one year low of $42.51 and a one year high of $135.70. The firm has a 50-day moving average of $72.48 and a two-hundred day moving average of $63.64.

CRISPR Therapeutics (NASDAQ:CRSP - Get Rating) last posted its quarterly earnings data on Monday, August 8th. The company reported ($2.40) EPS for the quarter, missing analysts' consensus estimates of ($2.21) by ($0.19). The firm had revenue of $0.20 million for the quarter, compared to analysts' expectations of $2.20 million. CRISPR Therapeutics had a negative net margin of 4,274.02% and a negative return on equity of 27.40%. CRISPR Therapeutics's quarterly revenue was down 100.0% compared to the same quarter last year. During the same period in the prior year, the company posted $9.44 earnings per share. As a group, equities research analysts predict that CRISPR Therapeutics will post -9.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Credit Suisse Group increased their target price on shares of CRISPR Therapeutics from $74.00 to $90.00 and gave the company a "neutral" rating in a research report on Tuesday. SVB Leerink decreased their target price on shares of CRISPR Therapeutics from $112.00 to $107.00 and set an "outperform" rating for the company in a research report on Monday, August 8th. The Goldman Sachs Group decreased their target price on shares of CRISPR Therapeutics from $52.00 to $46.00 and set a "neutral" rating for the company in a research report on Tuesday, May 24th. BMO Capital Markets assumed coverage on shares of CRISPR Therapeutics in a research report on Thursday, June 16th. They issued an "outperform" rating and a $98.00 target price for the company. Finally, Barclays lowered shares of CRISPR Therapeutics from an "overweight" rating to an "equal weight" rating and decreased their target price for the company from $99.00 to $88.00 in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $115.31.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 25,000 shares of the stock in a transaction that occurred on Wednesday, July 27th. The shares were sold at an average price of $75.91, for a total value of $1,897,750.00. Following the completion of the sale, the chief executive officer now directly owns 290,279 shares of the company's stock, valued at $22,035,078.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 10.70% of the stock is owned by insiders.